Drugs / BCMA-CS1 cCAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04156269 | Aug 2018 → Sep 2021 | plasma cell myeloma | iCell Gene Therapeutics | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCMA-CS1 cCAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04156269 ↗ |
| Known as | Compound CAR BCMA-CS1 | “BCMA-CS1 cCAR (Compound CAR BCMA-CS1) is a chimeric antigen receptor immunotherapy treatment designed to treat multiple myeloma using two different antigen targets, BCMA...” NCT04156269 ↗ |
| Action | Deplete | “intends to increase coverage and eradicate cancerous cells” NCT04156269 ↗ |
| Modality | Cell therapy | “BCMA-CS1 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-BCMA and CS1 CARs” NCT04156269 ↗ |
| Route | Intravenous | “by IV injection” NCT04156269 ↗ |